The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SHPH | -93.27% | N/A | N/A | -100% |
| S&P | +14.18% | +88.25% | +13.47% | +73% |
Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. It also offers cancer treatments with surgery, radiation therapy, chemotherapy, and immunotherapy. The company was founded by Anatoly Dritschilo, Mira Jung, and Milton Brown on December 18, 2012 and is headquartered in Rockville, MD.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | -27.1% |
| Market Cap | $3.80M | -3.0% |
| Market Cap / Employee | $0.42M | 0.0% |
| Employees | 9 | 12.5% |
| Net Income | -$2.35M | 38.0% |
| EBITDA | -$2.27M | 25.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.09M | 1237.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.18M | -31.4% |
| Short Term Debt | $0.49M | 59.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -507.78% | -279.5% |
| Return On Invested Capital | -210.39% | -188.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.63M | -31.4% |
| Operating Free Cash Flow | -$2.63M | -31.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.94 | 0.76 | 0.29 | 1.05 | -135.39% |
| Price to Tangible Book Value | -48.10 | 55.90 | 0.29 | 1.05 | -98.79% |
| Enterprise Value to EBITDA | -1.55 | -0.17 | -0.03 | -2.87 | 144.63% |
| Return on Equity | -383.8% | -346.2% | -551.0% | -27176.2% | 6251.74% |
| Total Debt | $1.17M | $1.10M | $0.71M | $0.67M | 18.27% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
